Moleculin Biotech (NASDAQ: MBRX) has announced that the Australian Patent Office (APO) has granted a patent with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity.
According to Moleculin, the base patent term will extend until June 2040—subject to extension to account for time required to fulfill requirements for regulatory approval.
In a statement, Walter Klemp, chairman and CEO of Moleculin, commented, “As we continue our mission to provide patients with Annamycin, a potentially transformative therapeutic candidate for hard-to-treat tumors, we remain focused on building our global patent protection to strengthen our competitive moat in oncology and bolster our position as a leader in the space. I am proud of our team’s diligent work in securing patent protection across key markets, and adding this Australian patent to our growing global IP portfolio underscores our commitment and belief in the potential of Annamycin. We remain encouraged by the data demonstrated by Annamycin to date and look forward to its continued advancement.”
